"Bei Asklepios steht der Mensch im Mittelpunkt. Unsere Mitarbeiterinnen und Mitarbeiter behandeln in unseren Klinken und Lehrkrankenhäusern bundesweit pro Jahr mehr als zwei Millionen Patientinnen und Patienten auf höchstem medizinischen Niveau nach höchsten Qualitätsstandards. Dabei verfolgen wir stets den Anspruch, jeder Patientin und jedem Patienten eine bestmögliche Behandlung in einem jederzeit sicheren Umfeld bei gleichzeitig persönlicher Zuwendung zukommen zulassen. Ob Krankenhaus der Maximalversorgung, spezialisierte Fach- oder Rehaklinik, bei uns werden Sie von hochqualifizierten Fachkräften nach modernsten medizinischen Standards versorgt."

During the past decade, Asklepios Klinik Wandsbek conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 2 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Asklepios Klinik Wandsbek" #1 sponsor was "Asklepios proresearch" with 2 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "University Hospital, Essen" with 2 trials sponsored, "Universitätsklinikum Hamburg-Eppendorf" with 1 trials sponsored and "Zoll Medical Corporation" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Asklepios Klinik Wandsbek" #1 collaborator was "Aesculap AG" with 1 trials as a collaborator, "Asklepios Kliniken GmbH & Co. KGaA" with 1 trials as a collaborator and "Ethicon Endo-Surgery" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Asklepios Klinik Wandsbek" are "ABDOMINAL SUBCUTANEOUS FAT" (1 trials), "Abdominal Aortic Aneurysm" (1 trials), "Brain Ischemia With Non-valvular Atrial Fibrillation" (1 trials), "COVID-19" (1 trials) and "Heart Failure" (1 trials). Many other conditions were trialed in "Asklepios Klinik Wandsbek" in a lesser frequency.

Most popular intervention types in "Asklepios Klinik Wandsbek" are "Drug" (3 trials), "Procedure" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "ASA 100 mg" (1 trials), "Dabigatran Etexilate Oral Capsule [Pradaxa]" (1 trials), "Dabigatran etexilate" (1 trials), "Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND]" (1 trials) and "Optilene® Mesh Elastic" (1 trials). Other intervention names were less common.

The vast majority of trials in "Asklepios Klinik Wandsbek" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Asklepios Klinik Wandsbek". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Asklepios Klinik Wandsbek, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Asklepios Klinik Wandsbek, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".